Choosing or switching to a single dose HPV vaccination can simplify delivery and lower program costs. It can also help reduce the potential for supply shortages and alleviate delivery challenges such as those encountered during the COVID-19 pandemic. Whether countries are in the initial stages of introducing the HPV vaccine or considering a switch, they have to face a few questions and challenges:
- What evidence is available to prove the efficacy of the single dose HPV vaccine and how does it compare to a two-dose or three-dose regimen? Are there issues with using vaccines off-label?
- What are the key reasons/tradeoffs to choose a single-dose HPV vaccination schedule?
- What lessons learned on the decision process, stakeholder engagement, communication, and implementation plan can be shared from countries which have introduced or switched to a single-dose? What can be learned from that process that could be applied to vaccine portfolio optimization as a whole?
Please join country representatives from Guyana and Estonia as they share their experiences introducing the HPV single dose schedule, along with global partners, to review the evidence, followed by a rich question and answer session, in which you will have the opportunity to ask questions and share your own experience.
Webinar: One-dose HPV vaccination: Evidence, lessons learned and strategies, with experiences from Guyana and Estonia
Date: 9 October 2024 at 8am EST \\ 2pm CEST
Please make sure to register for this event and let us know if you will require translation support here: https://r4d-org.zoom.us/webinar/register/WN_Av21Lx-iRpu6ANYQRcpJmQ.